èšåºæ®µéã®ãã€ãªå»è¬åäŒæ¥ã§ããCorvus Pharmaceuticals, Inc.ã¯ãå
ç«è
«çåŠçæ³ã®éçºãšåååã«éç¹ã眮ããŠããŸããäž»å補ååè£ã¯ãCOVID-19ã«å¯ŸããCPI-006ã®ç¬¬IIIçžèšåºè©ŠéšãšããŠãã¢ããã·ã³ã®ç£çãé»å®³ããããŸããŸãªå
ç«çްèãæŽ»æ§åããã第I/Ibçžèšåºè©Šéšäžã®æCD73ã¢ãã¯ããŒãã«æäœCPI-006ã§ããå瀟ã¯ãŸããããŸããŸãªæªæ§T现èãªã³ãè
«ã®æ£è
ã®æ²»çãç®çãšãã第I/Ibçžèšåºè©Šéšäžã®ITKã®å
±æçµååé»å®³å€CPI-818ãããã³å
ç«ãã§ãã¯ãã€ã³ãã§ããã¢ããã·ã³ã®ç¬¬Ib/IIçžèšåºè©Šéšäžã®A2Aå容äœã®çµå£å°ååæ®æè¬Ciforadenant (CPI-444)ãéçºããŠããŸããåèšåºæ®µéã®è£œåã«ã¯ã奜äžçã®æ©èœãšéèµ°ãããã³éªšé«ç±æ¥æå¶çްèãé»å®³ããæäœCPI-182ããããŸãããŸããç·ç¶çãäºé²ããã¢ããã·ã³ A2B åå®¹äœæ®æè¬ CPI-935 ãéçºããŠããŸããCorvus Pharmaceuticals, Inc. ã¯ãæšçæ²»éšè¬ã®ãã€ãã©ã€ã³ã®éçºã§ Angel Pharmaceuticals ãšæŠç¥çææºãçµãã§ããŸããå瀟㯠2014 幎ã«èšç«ãããã«ãªãã©ã«ãã¢å·ããŒãªã³ã²ãŒã ã«æ ç¹ã眮ããŠããŸãã